Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Crohn Disease

Interventions

DEVICE: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System
DRUG: Prednisone/Methylprenisolone
DRUG: Palifermin
DRUG: ATG
DRUG: Clofarabine
DRUG: Melphalan
RADIATION: Total Body Irradiation
DRUG: Rituximab

Sponsor

Stanford University